Analysts Set Pharmerica Corporation (PMC) PT at $29.25
Pharmerica Corporation (NYSE:PMC) has earned an average recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $29.25.
Several brokerages recently issued reports on PMC. Barrington Research downgraded shares of Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a research report on Wednesday, August 9th. KeyCorp downgraded shares of Pharmerica Corporation to an “overweight” rating in a research report on Tuesday, August 8th. Credit Suisse Group downgraded shares of Pharmerica Corporation from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $29.00 to $29.25 in a research report on Friday, August 4th. They noted that the move was a valuation call. UBS AG reiterated a “neutral” rating and set a $29.25 price target (up previously from $26.00) on shares of Pharmerica Corporation in a research report on Thursday, August 3rd. Finally, BidaskClub downgraded shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st.
A number of hedge funds and other institutional investors have recently modified their holdings of PMC. Phocas Financial Corp. increased its position in shares of Pharmerica Corporation by 4.7% in the second quarter. Phocas Financial Corp. now owns 273,788 shares of the company’s stock valued at $7,187,000 after buying an additional 12,214 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Pharmerica Corporation during the second quarter worth about $200,000. Public Employees Retirement System of Ohio increased its position in Pharmerica Corporation by 10.5% in the second quarter. Public Employees Retirement System of Ohio now owns 5,028 shares of the company’s stock worth $132,000 after buying an additional 476 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Pharmerica Corporation by 0.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,228 shares of the company’s stock worth $610,000 after buying an additional 71 shares during the last quarter. Finally, State Street Corp increased its position in Pharmerica Corporation by 1.6% in the second quarter. State Street Corp now owns 808,831 shares of the company’s stock worth $21,236,000 after buying an additional 12,607 shares during the last quarter. Institutional investors and hedge funds own 92.35% of the company’s stock.
Shares of Pharmerica Corporation (PMC) traded down 0.17% during mid-day trading on Monday, reaching $29.15. 431,472 shares of the company traded hands. The stock has a market capitalization of $907.18 million, a PE ratio of 39.50 and a beta of 0.92. The stock’s 50 day moving average is $27.40 and its 200 day moving average is $25.23. Pharmerica Corporation has a 52-week low of $19.20 and a 52-week high of $29.20.
Pharmerica Corporation (NYSE:PMC) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.47. The business had revenue of $592 million for the quarter, compared to the consensus estimate of $592.96 million. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The firm’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 EPS. On average, analysts anticipate that Pharmerica Corporation will post $1.92 earnings per share for the current year.
Pharmerica Corporation Company Profile
Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.